Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy

被引:20
|
作者
Weinberg, A
Wiznia, AA
LaFleur, BJ
Shah, S
Levin, MJ
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Med, Sect Pediat Infect Dis, Denver, CO 80262 USA
[2] Univ Colorado, Sch Med, Dept Med, Denver, CO 80262 USA
[3] Indiancrest Pediat, Westminster, CO USA
[4] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA
[5] Jacobi Med Ctr Family Based Serv, Pediat HIV Serv, Bronx, NY USA
来源
JOURNAL OF INFECTIOUS DISEASES | 2004年 / 190卷 / 02期
关键词
D O I
10.1086/422011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Herpes zoster (HZ) is a frequent complication of advanced human immunodeficiency virus (HIV) infection. We determined the effect of highly active antiretroviral therapy (HAART) on reconstitution of varicella-zoster virus (VZV) specific cell-mediated immunity (VZV-CMI) in 56 VZV- and HIV-infected children. VZV-CMI did not change over the course of greater than or equal to3 years of observation, despite a reduction in HIV load. VZV- CMI correlated with lower HIV load but not with CD4 cell percentage. The incidence of HZ was unaffected by HAART. None of 5 patients who developed HZ during the study had VZV- CMI before developing HZ. After developing HZ, only the 2 HAART-compliant patients developed VZV- CMI. Thus, VZV- specific immune reconstitution in HIV infection may require antigenic reexposure, in addition to control of HIV replication.
引用
收藏
页码:267 / 270
页数:4
相关论文
共 50 条
  • [31] Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy
    Sevastianova, K
    Sutinen, J
    Westerbacka, J
    Ristola, M
    Yki-Järvinen, H
    [J]. ANTIVIRAL THERAPY, 2005, 10 (08) : 925 - 935
  • [32] Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy
    Patel, V
    Hedayati, SS
    [J]. NATURE CLINICAL PRACTICE NEPHROLOGY, 2006, 2 (02): : 109 - 114
  • [33] Osteonecrosis in six HIV-infected patients receiving highly active antiretroviral therapy
    Molia, AC
    Strady, C
    Rouger, C
    Beguinot, IM
    Berger, JL
    Trenque, TC
    [J]. ANNALS OF PHARMACOTHERAPY, 2004, 38 (12) : 2050 - 2054
  • [34] Subdinical hypothyroidism in HIV-infected patients receiving highly active antiretroviral therapy
    Calza, L
    Manfredi, R
    Chiodo, F
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (03) : 361 - 363
  • [35] Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy
    Risa, KJ
    Nepon, L
    Justis, JC
    Panwalker, A
    Berman, SM
    Cinti, S
    Wagener, MM
    Singh, N
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2002, 13 (10) : 706 - 713
  • [36] Effect of HIV/AIDS and Highly Active Antiretroviral Therapy (HAART) on the Serologic Response to Varicella-Zoster Infection
    Patricia Mullen
    Ninad Desai
    Hermann Mendez
    [J]. Pediatric Research, 1999, 45 : 169 - 169
  • [37] Effect of HIV/AIDS and highly active antiretroviral therapy (HAART) on the serologic response to varicella-zoster infection
    Mullen, P
    Desai, N
    Mendez, H
    [J]. PEDIATRIC RESEARCH, 1999, 45 (04) : 169A - 169A
  • [38] Detection of Varicella-Zoster virus-specific cellular immunity in patients with acute lymphoblastic leukaemia
    Alejenef, A.
    Albarbar, B.
    Caswell, M.
    Pizer, B.
    Keenan, R.
    Manley, S.
    Khan, N.
    [J]. IMMUNOLOGY, 2010, 131 : 61 - 61
  • [39] Comparison of Varicella-Zoster Virus-Specific Immunity of Patients with Diabetes Mellitus and Healthy Individuals
    Okamoto, Shigefumi
    Hata, Atsuko
    Sadaoka, Kay
    Yamanishi, Koichi
    Mori, Yasuko
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (10): : 1606 - 1610
  • [40] Reduction in the Number of Varicella-Zoster Virus-Specific T-Cells in Immunocompromised Children with Varicella
    Murata, Kenji
    Hoshina, Takayuki
    Onoyama, Sagano
    Tanaka, Tamami
    Kanno, Shunsuke
    Ishimura, Masataka
    Koga, Yuhki
    Nakayama, Hideki
    Ohga, Shouichi
    [J]. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2020, 250 (03): : 181 - 190